دورية أكاديمية
Le médicament du mois. Combinaison fixe budésonide, formotérol, glycopyronium pour le traitement de la BPCO modérée à sévère : Trixeo Aerosphère®.
| العنوان: | Le médicament du mois. Combinaison fixe budésonide, formotérol, glycopyronium pour le traitement de la BPCO modérée à sévère : Trixeo Aerosphère®. Fixed combination of budesonide, formoterol, glycopyrronium for the treatment of severe COPD : Trixeo Aerosphere®. |
|---|---|
| المؤلفون: | Louis, Renaud, Bonhomme, Olivier, HEINEN, Vincent, NGUYEN DANG, Delphine, VAN CAUWENBERGE, Hélène, Corhay, Jean-Louis |
| المصدر: | Revue Médicale de Liège, 77 (4), 244-248 (2022-04) |
| بيانات النشر: | Université de Liège. Revue Médicale de Liège, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Adrenal Cortex Hormones, Adrenergic Agonists, Bronchodilator Agents, Drug Combinations, Budesonide, V92SO9WP2I (Glycopyrrolate), W34SHF8J2K (Formoterol Fumarate), Administration, Inhalation, Adrenal Cortex Hormones/therapeutic use, Adrenergic Agonists/therapeutic use, Bronchodilator Agents/pharmacology/therapeutic use, Budesonide/therapeutic use, Formoterol Fumarate/pharmacology/therapeutic use, Glycopyrrolate/therapeutic use, Humans, Metered Dose Inhalers, Pulmonary Disease, Chronic Obstructive/drug therapy, Quality of Life, COPD, Exacerbations, Fixed combination budesonide, formoterol, glycopyrronium, Mortality, Trixeo Aerosphere®, Human health sciences, Cardiovascular & respiratory systems, Sciences de la santé humaine, Systèmes cardiovasculaire & respiratoire |
| الوصف: | editorial reviewed Here we present pharmacological and clinical properties of a new fixed triple inhaled combination including an inhaled corticoid, a long acting ?2 agonist and a long acting anticholinergic for the treatment of severe chronic obstructive pulmonary disease (COPD). Trixeo Aerosphere® is the name of this triple combination which contains 160 µg budesonide, 4,8 µg formoterol and 9 µg glycopyrronium delivered by a pMDI. As compared to a budesonide/formoterol combination, Trixeo Aerosphere® improves forced expiratory volume in the first second (FEV1). As compared to glycopyrronium/formoterol combination, Trixeo Aerosphere® reduces exacerbation rate, improved quality of life and most importantly reduces mortality with a benefit increasing with blood eosinophil count. Trixeo Aerosphere® 320/18/9.6 is delivered twice daily 2 inhalations and is indicated in moderate to severe COPD insufficiently controlled by LABA/LAMA (long-acting ?2-adrenergic receptor agonist/ long-acting ?2-muscarinic receptor agonist) or ICS/LABA (inhaled corticosteroid/long-acting ?2-adrenergic receptor agonist). |
| نوع الوثيقة: | journal article http://purl.org/coar/resource_type/c_6501Test article editorial reviewed |
| اللغة: | French |
| العلاقة: | urn:issn:0370-629X; urn:issn:2566-1566 |
| الوصول الحر: | https://orbi.uliege.be/handle/2268/299862Test |
| حقوق: | embargoed access http://purl.org/coar/access_right/c_f1cfTest info:eu-repo/semantics/embargoedAccess |
| رقم الانضمام: | edsorb.299862 |
| قاعدة البيانات: | ORBi |
| الوصف غير متاح. |